Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Europe To Resume AZ Vaccine Use After Safety Review, But Confidence Knocked

Rare But Serious Events Being Monitored

Executive Summary

The EMA’s conclusions are in line with those of the UK regulator and the World Health Organization, but EU countries’ stop-start decisions will have done nothing to boost the public’s trust in the vaccine.

You may also be interested in...



EMA Using Real World Data To Assess Safety Of COVID-19 Vaccines

The EMA is investigating possible links between the three COVID-19 vaccines currently being used in Europe and cases of thrombotic events. It is also planning safety studies in targeted populations.

EU Explains Plans To Speed Up Variant Vaccine Approvals

The EU institutions are taking steps to preserve the effectiveness of existing vaccines in the face of mutations in the SARS-CoV-2 virus.

AstraZeneca Vaccine’s ‘Big Gap’: DSMB Questions Results Released By Firm In Latest Controversy

‘Harsh note’ from Data Safety and Monitoring Board follows AstraZeneca press release that contained incomplete information about the Phase III US trial for its COVID vaccine. It remains to be seen how the company will fix this ‘unforced error’ and weather the latest threat to public trust.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel